These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 5941178)

  • 21. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YELLOW FEVER VACCINATION IN MALAYA BY SUBCUTANEOUS INJECTION AND MULTIPLE PUNCTURE. HAEMAGGLUTININ-INHIBITING ANTIBODY RESPONSES IN PERSONS WITH AND WITHOUT PRE-EXISTING ANTIBODY.
    SMITH CE; MCMAHON DA; TURNER LH
    Bull World Health Organ; 1963; 29(1):75-80. PubMed ID: 14043754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of yellow fever vaccine.
    Monath TP
    Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus.
    WISSEMAN CL; SWEET BH; KITAOKA M; TAMIYA T
    Am J Trop Med Hyg; 1962 Jul; 11():550-61. PubMed ID: 14007700
    [No Abstract]   [Full Text] [Related]  

  • 25. Yellow fever vaccine. 3. Antibody response in monkeys inoculated with a vaccine free from contaminating avian leukosis viruses.
    Tauraso NM; Spector SL; Trimmer RW
    Arch Gesamte Virusforsch; 1972; 37(2):211-7. PubMed ID: 4337545
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory infection with Zika virus after vaccination against yellow fever.
    Filipe AR; Martins CM; Rocha H
    Arch Gesamte Virusforsch; 1973; 43(4):315-9. PubMed ID: 4799154
    [No Abstract]   [Full Text] [Related]  

  • 28. TWO EPISODES OF DENGUE FEVER, CAUSED BY TYPES 4 AND 1 VIRUSES, IN AN INDIVIDUAL PREVIOUSLY IMMUNIZED AGAINST YELLOW FEVER.
    CAREY DE; MYERS RM; RODRIGUES FM
    Am J Trop Med Hyg; 1965 May; 14():448-50. PubMed ID: 14292751
    [No Abstract]   [Full Text] [Related]  

  • 29. [Is there an alternative to the amaril 17D vaccine?].
    Saluzzo JF
    Bull Soc Pathol Exot; 1999 Dec; 92(5 Pt 2):436. PubMed ID: 11000959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemagglutination-inhibiting antibodies to arboviruses in the human population in Thailand.
    Sekeyová M; Gresiková M
    J Hyg Epidemiol Microbiol Immunol; 1969; 13(3):288-92. PubMed ID: 5387795
    [No Abstract]   [Full Text] [Related]  

  • 31. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis.
    Holzmann H; Kundi M; Stiasny K; Clement J; McKenna P; Kunz C; Heinz FX
    J Med Virol; 1996 Jan; 48(1):102-7. PubMed ID: 8825718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine.
    Mason RA; Tauraso NM; Spertzel RO; Ginn RK
    Appl Microbiol; 1973 Apr; 25(4):539-44. PubMed ID: 4633476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.
    Bonaldo MC; Garratt RC; Marchevsky RS; Coutinho ES; Jabor AV; Almeida LF; Yamamura AM; Duarte AS; Oliveira PJ; Lizeu JO; Camacho LA; Freire MS; Galler R
    J Virol; 2005 Jul; 79(13):8602-13. PubMed ID: 15956601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative clinical study of a new 17D thermostable yellow fever vaccine.
    Roche JC; Jouan A; Brisou B; Rodhain R; Fritzell B; Hannoun C
    Vaccine; 1986 Sep; 4(3):163-5. PubMed ID: 3532602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agglutination of African rodent and primate erythrocytes by arboviruses and the susceptibility of some of these animals to yellow fever and Kadam viruses.
    Mutanda LN; Munube GM
    Acta Virol; 1972 May; 16(3):258-63. PubMed ID: 4402256
    [No Abstract]   [Full Text] [Related]  

  • 37. A serological survey on arbovirus antibodies in the Sudan.
    Salim AR; Porterfield JS
    Trans R Soc Trop Med Hyg; 1973; 67(2):206-10. PubMed ID: 4784057
    [No Abstract]   [Full Text] [Related]  

  • 38. Stability of 17D yellow fever virus vaccine using different stabilizers.
    Adebayo AA; Sim-Brandenburg JW; Emmel H; Olaleye DO; Niedrig M
    Biologicals; 1998 Dec; 26(4):309-16. PubMed ID: 10403034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein.
    Bonaldo MC; Garratt RC; Freire MS; Galler R
    Cell Biochem Biophys; 2006; 44(3):313-24. PubMed ID: 16679518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.